Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Esperion Therapeutics, Inc.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Taking daily stable statin doses for at least 4 weeks prior to screening visit.
LDL-C between 100-220 mg/dL for patients taking daily high-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit; or,
LDL-C between 115-220 mg/dL for patients taking moderate- or low-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit.
Must be willing to discontinue other lipid-regulating therapies during the study
You may not be if
History of acute significant cardiovascular disease.
Current clinically significant cardiovascular disease.
History of inability to tolerate any statin at any dose due to muscle-related pain or weakness.
Clareo Health | A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
